Production and characterization of drug-loaded toroidal vortices from a novel ocular drug delivery device

2018 ◽  
Vol 8 (5) ◽  
pp. 1139-1151 ◽  
Author(s):  
Matthew J. Herpin ◽  
Dominik Ebi ◽  
Noel T. Clemens ◽  
Hugh D. C. Smyth
Keyword(s):  
Drug Delivery ◽  
Ocular Drug Delivery ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
Toroidal Vortices

In vivo tolerance and kinetics of a novel ocular drug delivery device

2006 ◽  
Vol 116 (2) ◽  
pp. e47-e49 ◽  
Author(s):  
R.T. Pijls ◽  
H.H.L. Hanssen ◽  
R.M.M.A. Nuijts ◽  
G.W. Daube ◽  
L.H. Koole
Keyword(s):  
Drug Delivery ◽  
Ocular Drug Delivery ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
Kinetics Of

DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial Chemoembolization

2006 ◽  
Vol 17 (2) ◽  
pp. 335-342 ◽  
Author(s):  
Andrew L. Lewis ◽  
M. Victoria Gonzalez ◽  
Andrew W. Lloyd ◽  
Brenda Hall ◽  
Yiqing Tang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Transarterial Chemoembolization ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
In Vitro Characterization

An Implantable Device Design Concept for Ocular Drug Delivery

2012 ◽  
Author(s):  
Jae-Hwan Lee ◽  
Ramana M. Pidaparti
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Ocular Drug Delivery ◽  
Eye Diseases ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
Age Related ◽  
Intraocular Hemorrhage

New drugs for curing eye diseases have been developing for a decade and are very unique for each eye diseases such as glaucoma, cataracts, and age-related macular degeneration (AMD). It is estimated that 1.6 million adults in the US over the age of 50 and above suffer from age-related macular degeneration and about 200,000 cases are diagnosed annually. Worldwide, about 500,000 cases are diagnosed annually [1]. Drugs currently utilized for AMD are delivered via repeated intravitreal injections of the drug into the eye. Risks of repeated intravitreal injections can include intraocular infections (endophthalmitis), intraocular hemorrhage, and retinal detachment. Also, reducing the frequency of dosing will clearly benefit the patient by reducing the need for risky intravitreal injections and improving the pharmacokinetics of the drug in the eye. The eye disease of posterior segment (Dry and Wet) has limits to deliver the drug to retina region using typical eye drop. The drug injection using a needle with syringe can deliver but it barely provide right amount of doses, or over doses that may cause more severe problem such as swelling, fatigue, and damaging photoreceptor molecules. Furthermore, most drugs run away in a month so that repeated injection is necessary. Developing an implantable drug delivery device will help reduce the costs and risks associated with frequent injections and facilitate delivering the drug in a controlled manner and in the required amounts, and improve therapeutic efficacy and safety of drugs. This study focuses on the design, simulation and development of the implantable ocular drug delivery device.

scholarly journals Design and in Vitro Biocompatibility of a Novel Ocular Drug Delivery Device

2013 ◽  
Vol 4 (1) ◽  
pp. 14-26 ◽  
Author(s):  
Nathan Gooch ◽  
Randon Burr ◽  
Dolly Holt ◽  
Bruce Gale ◽  
Balamurali Ambati
Keyword(s):  
Drug Delivery ◽  
Ocular Drug Delivery ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
In Vitro Biocompatibility
Sign in / Sign up

Export Citation Format

Share Document